Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01EB10 Mobocertinib
D11969 Mobocertinib succinate (JAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Endothelial Growth Factor Inhibitors
Mobocertinib
D11969 Mobocertinib succinate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03148 Mobocertinib
D11969 Mobocertinib succinate
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG03148 Mobocertinib
D11969 Mobocertinib succinate
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR* [HSA_VAR:1956v2]
D11969 Mobocertinib succinate (JAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11969
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11969
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11969
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11969
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03148 Mobocertinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG03148 Mobocertinib